menu
    • menu

    Company profile for Tempest Therapeutics

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Tempest has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response. Tempest has assembled an experienced team of small molecule and immuno-oncology drug developers to advance these programs to the clinic across diverse cancers representing significant unmet medical need. Tempest is backed by ...
    Tempest has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response. Tempest has assembled an experienced team of small molecule and immuno-oncology drug developers to advance these programs to the clinic across diverse cancers representing significant unmet medical need. Tempest is backed by a syndicate of leading US and China-based venture capital firms.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Tempest TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    7000 Shoreline Court Suite 275 South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.tempesttx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/tempesttx
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tempest Closes $8.35M Stock Offering With Warrant Placement
    Tempest Closes $8.35M Stock Offering With Warrant Placement

    26 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/26/3195383/0/en/Tempest-Announces-Closing-of-Up-To-8-35-Million-Registered-Direct-Offering-of-Common-Stock-and-Concurrent-Private-Placement-of-Warrants-Priced-At-the-Market-Under-Nasdaq-Rules.html

    GLOBENEWSWIRE
    26 Nov 2025
    Share Share
    Tempest Initiates $8.35M Stock Offering With Warrant Placement
    Tempest Initiates $8.35M Stock Offering With Warrant Placement

    25 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/25/3194293/0/en/Tempest-Announces-Up-To-8-35-Million-Registered-Direct-Offering-of-Common-Stock-and-Concurrent-Private-Placement-of-Warrants-Priced-At-the-Market-Under-Nasdaq-Rules.html

    GLOBENEWSWIRE
    25 Nov 2025
    Share Share
    Tempest Acquires Factor's Dual-Car T Programs, Extends Runway
    Tempest Acquires Factor's Dual-Car T Programs, Extends Runway

    19 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/19/3191025/0/en/Tempest-Announces-Strategic-Acquisition-of-New-Dual-CAR-T-Programs-from-Factor-with-Simultaneous-Runway-Extension-Projected-to-Mid-2027.html

    GLOBENEWSWIRE
    19 Nov 2025
    Share Share
    Tempest Unveils Q3 2025 Financials & Business Update
    Tempest Unveils Q3 2025 Financials & Business Update

    05 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/05/3181474/0/en/Tempest-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    05 Nov 2025
    Share Share
    Tempest's Q2 2025 Financial Results and Business Update
    Tempest's Q2 2025 Financial Results and Business Update

    11 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/11/3131269/0/en/Tempest-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    11 Aug 2025
    Share Share
    Tempest Gets China Clearance for HCC Trial of Amezalpat
    Tempest Gets China Clearance for HCC Trial of Amezalpat

    30 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/30/3107414/0/en/Tempest-Receives-Clearance-to-Proceed-with-Pivotal-Trial-of-Amezalpat-Combination-Therapy-for-First-Line-HCC-in-China.html

    GLOBENEWSWIRE
    30 Jun 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search